Aardvark Therapeutics
Signal active
Organization
Contact Information
Overview
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
Aardvark Therapeutics was founded by Tien Lee in 2017.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2017
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Aardvark Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $4.6B in funding across 36 round(s). With a team of 11-50 employees, Aardvark Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series C - Aardvark Therapeutics, raised $85.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
13
Lead Investors
0
Total Funding Amount
$129.0M
Details
3
Aardvark Therapeutics has raised a total of $129.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2021 | Early Stage Venture | 29.0M | ||
| 2019 | Early Stage Venture | 15.0M | ||
| 2024 | Late Stage Venture | 85.0M |
Investors
Aardvark Therapeutics is funded by 38 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Cormorant Asset Management | - | FUNDING ROUND - Cormorant Asset Management | 85.0M |
| Stacy Ward | - | FUNDING ROUND - Stacy Ward | 85.0M |
| Aardvark Therapeutics | - | FUNDING ROUND - Aardvark Therapeutics | 85.0M |
| The Prader-Willi Syndrome Association – USA | - | FUNDING ROUND - The Prader-Willi Syndrome Association – USA | 85.0M |
Recent Activity
There is no recent news or activity for this profile.